drugset / Trial / NCT00520234

Randomized Study of Caspofungin Prophylaxis Followed by Pre-emptive Therapy for Invasive Candidiasis in the Intensive Care Unit (ICU)

NCT00520234

RandomizedParallel-groupQuadruple-blindPrevention

Summary

Adults admitted to intensive care units are at risk for a variety of complications. Infections due to the fungus called candida are of particular concern. The study will test the possibility that caspofungin, a new therapy for fungal infections, can successfully reduce the rate of candida infections in subjects at risk. It will also test if caspofungin is useful in treating subjects for this disease when diagnosed using a new blood test that is performed twice weekly, permitting earlier diagnosis than current practice standards.

Timeline

Start
2007-08
Primary completion
2010-03
Completion
2010-03

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Caspofungin Other / unclassified 50 mg Intravenous

Indications